Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Glioblastoma 3Glioma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lipodystrophy, Congenital Generalized 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Astrocytoma 1Advanced Cancer 1

Interventions

Dexamethasone 277Lenalidomide 155Bortezomib 152Cyclophosphamide 115Melphalan 107Calcium Dobesilate 107fludarabine phosphate 70carfilzomib 61pomalidomide 55Peripheral Blood Stem Cell Transplantation 53Whole-Body Irradiation 52Mycophenolic Acid 52Granulocyte Colony-Stimulating Factor 52Filgrastim 52daratumumab 46fludarabine 43Tacrolimus 41ixazomib 40Busulfan 40Thalidomide 36Cyclosporine 32dexamethasone acetate 26Stem Cell Transplantation 26Antilymphocyte Serum 25dexamethasone 21-phosphate 22plerixafor 20auricularum 20belantamab mafodotin 19Prednisone 19Etoposide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Multiple Myeloma × Tetanus Toxoid × Clear all
NCT02700841 2024-03-12

Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

University of Nebraska

Phase 2 Terminated
8 enrolled 8 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡